NCT06152809 2026-03-18CIML NK Cells With Venetoclax for AMLDana-Farber Cancer InstitutePhase 1 Recruiting10 enrolled
NCT03666000 2026-02-02Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)Imugene LimitedPhase 1 Recruiting135 enrolled
NCT06138587 2026-01-02Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell TransplantationDana-Farber Cancer InstitutePhase 1 Recruiting15 enrolled
NCT06119685 2025-06-03IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic CancersIndapta Therapeutics, INC.Phase 1/2 Recruiting128 enrolled
NCT06256627 2024-02-13The Maintenance Treatment of "ITIVA" in AML PatientsHenan Cancer HospitalPhase NA Recruiting130 enrolled